Key result
HF and respiratory phenotypes linked to ~27% higher 12-month mortality vs hypertensive/metabolic phenotypes in older AF.
Why the study?
Most older patients with AF have comorbidities, but whether specific comorbidity patterns are associated with adverse outcomes was unclear.
Does comorbidity phenotype affect 12-month mortality in older hospitalised patients with non-valvular atrial fibrillation?
Cohort (n=2,019)
Yes
Does comorbidity phenotype affect 12-month mortality in older hospitalised patients with non-valvular atrial fibrillation?
Effect estimate: adjusted HR 1.27 (95% CI 1.01 to 1.60)
In older hospitalised patients with non-valvular AF, a comorbidity phenotype characterized by heart failure and respiratory diseases is associated with a higher risk of 12-month mortality compared to a phenotype of hypertension and metabolic diseases.
May inform prognosis by comorbidity phenotype in older AF patients; leaves open whether targeted interventions improve outcomes.
BACKGROUND: Most older patients with atrial fibrillation (AF) have comorbidities. However, it is unclear whether specific comorbidity patterns are associated with adverse outcomes. We identified comorbidity patterns and their association with mortality in multimorbid older AF patients with different multidimensional frailty. METHODS: Hospitalised adults aged ≥65 years with non-valvular AF were followed for 12 months in the multicentre EURopean study of Older Subjects with Atrial Fibrillation (EUROSAF). Demographic characteristics, coexisting medical conditions, use of medications including anticoagulants, and the Multidimensional Prognostic Index (MPI) were captured on discharge. We used latent class analysis (LCA) to identify comorbidity phenotypes and Cox regression to determine associations between identified phenotypes and 12-month mortality. RESULTS: = 2,019 AF patients (mean ± SD age 82.9 ± 7.5 years), a 3-class LCA solution was considered optimal for phenotyping. The model identified phenotype 1 (hypertensive, other circulatory conditions, metabolic diseases; 33%), phenotype 2 (digestive diseases, infection, injury, non-specific clinical and laboratory abnormalities; 26%), and phenotype 3 (heart failure, respiratory diseases; 41%). Overall, 512 patients (25%) died within 12 months. Compared to phenotype 1, after adjusting for age, sex, use of anticoagulants, cardiovascular medications, and proton pump inhibitors, and individual MPI domains, phenotype 3 had a significantly higher risk of mortality (adjusted hazard ratio = 1.27, 95% CI = 1.01 to 1.60). In contrast, the risk of mortality in phenotype 2 was not different to phenotype 1. CONCLUSION: We observed an association between comorbidity phenotypes identified using LCA and mortality in older AF patients. Further research is warranted to identify the mechanisms underpinning such associations.
No takes yet. Share an insight, caveat, or question.
Ng et al. (2025) conducted a cohort in non-valvular atrial fibrillation (n=2,019). Comorbidity phenotype 3 (heart failure, respiratory diseases) vs. Comorbidity phenotype 1 (hypertensive, other circulatory conditions, metabolic diseases) was evaluated on 12-month mortality (adjusted HR 1.27, 95% CI 1.01 to 1.60). A heart failure and respiratory disease comorbidity phenotype increased 12-month mortality in older AF patients compared to a hypertensive/metabolic phenotype (adjusted HR 1.27; 95% CI 1.01-1.60).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: